Also from this source


You just read:

Abide Therapeutics Announces Celgene Option Exercise to Develop ABX-1431, an Investigational Endocannabinoid System Modulator for Patients with Neurological Diseases

News provided by

Abide Therapeutics

29 Sep, 2016, 08:00 ET